Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
An old cancer drug's degrading new look: Typically, cancer drugs that help only a small number of patients in clinical trials are not pursued. This might change in a future world of precision medicine, where biomarkers will match specific drugs to the patients most likely to respond. Han et al. identified the mechanism of action of a cancer drug called indisulam, a sulfonamide tested previously in patients with solid tumors. Indisulam and related sulfonamides killed cells by disrupting precursor mRNA splicing. The drugs targeted a specific RNA splicing factor for degradation by “gluing” it to the CUL4-DCAF15 ubiquitin ligase. Experiments with cancer cell lines suggest that future clinical trials of these drugs should focus on leukemias and lymphomas with high DCAF15 expression levels. Science , this issue p. eaal3755
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, aryl sulphonamides degrade the essential RNA-binding protein RBM39 by engaging DCAF15, the substrate receptor of the CRL4DCAF15 E3 ubiquitin ligase13–15.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [13]
In the citing paper
“it took two decades to determine that indisulam, and the related sulfonamides e7820 and chloroquinoxaline sulfonamide (cQS), were in fact glue degraders that targeted the splicing factor RBM39 (Han et al. 2017;uehara et al. 2017).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Han et al. 2017
In the citing paper
“indisulam facilitated an interaction between RBM39 and DcAF15, a substrate receptor component of the cRl4 DcAF15 ligase complex (Han et al. 2017;uehara et al. 2017).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Han et al. 2017
In the citing paper
“However, sulfonamides such as indisulam and similar SPlAMs were serendipitously discovered to degrade RBM39 by stabilizing its native interaction with cRl4 DcAF15 (Han et al. 2017; uehara et al. 2017) (Figure 4A).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Han et al. 2017
In the citing paper
“The same MG mechanism has subsequently been revealed for antitumor aryl-sulfonamides, which reprograms another CRL4 substrate receptor, DCAF15, to bind and degrade certain RNA-binding proteins21–26.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [21]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668 · cited 1×
“8) (52) to human reference genome (hg19) along with the gene annotation data downloaded from Illumina’s iGenomes (http://support.”
MethodMass Spectrometric Sequencing of Proteins from Silver-Stained Polyacrylamide Gels
Shevchenko, A., Wilm, M., Vorm, O., & Mann, M. (1996) · Analytical Chemistry · doi:10.1021/ac950914h · Cited by 8,995
Eng, J. K., McCormack, A. L., & Yates, J. R. (1994) · Journal of the American Society for Mass Spectrometry · doi:10.1016/1044-0305(94)80016-2 · Cited by 6,484 · cited 2×
“As peptides eluted they were subjected to electrospray ionization and then entered into an LTQ Orbitrap Velos Pro ion-trap mass spectrometer (Thermo Fisher Scientific, Waltham, MA).”
MethodNGS QC Toolkit: A Toolkit for Quality Control of Next Generation Sequencing Data
Patel, R. K., & Jain, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030619 · Cited by 2,917
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990 · cited 7×
“In many cases, ubiquitin is added to substrates by cullinRING ligases (CRLs), which are multisubunit ubiquitin ligases (23).”
BackgroundInfluentialLenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Mechanism of auxin perception by the TIR1 ubiquitin ligase
Tan, X., Calderon-Villalobos, L. I. A., Sharon, M., Zheng, C., Robinson, C. V., Estelle, M., & Zheng, N. (2007) · Nature · doi:10.1038/nature05731 · Cited by 1,688 · cited 1×
“This is the same mechanism by which the plant hormone auxin acts like “molecular glue” to enhance an interaction between the E3 ubiquitin ligase receptor TIR1 and its substrates (43).”
Background
Cited by
Items 101–200 of 786
Riching, K. M., Caine, E. A., Urh, M., & Daniels, D. L. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00339b · Cited by 113
Cereblon modulators: Low molecular weight inducers of protein degradation
Chamberlain, P. P., & Cathers, B. E. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2019.02.004 · Cited by 106
Splicing factor mutations in hematologic malignancies
Chen, S., Benbarche, S., & Abdel-Wahab, O. I. (2021) · Blood · doi:10.1182/blood.2019004260 · Cited by 119
Nishiguchi, G., Keramatnia, F., Min, J., Chang, Y., Jonchere, B., Das, S., Actis, M., Price, J., Chepyala, D., Young, B., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01313 · Cited by 99
In vivo target protein degradation induced by PROTACs based on E3 ligase DCAF15
Li, L., Mi, D., Pei, H., Duan, Q., Wang, X., Zhou, W., Jin, J., Li, D., Liu, M., & Chen, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00245-0 · Cited by 90
Mechanistic and Structural Features of PROTAC Ternary Complexes
Casement, R., Bond, A. G., Craigon, C., & Ciulli, A. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1665-9_5 · Cited by 107
Bifunctional chemical probes inducing protein–protein interactions
Maniaci, C., & Ciulli, A. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.07.003 · Cited by 100
Pech, M. F., Fong, L. E., Villalta, J. E., Chan, L. J., Kharbanda, S., O’Brien, J. J., McAllister, F. E., Firestone, A. J., Jan, C. H., & Settleman, J. E. (2019) · eLife · doi:10.7554/elife.47362 · Cited by 104
Function, clinical application, and strategies of Pre-mRNA splicing in cancer
Di, C., Syafrizayanti, S., Zhang, Q., Chen, Y., Wang, Y., Zhang, X., Liu, Y., Sun, C., Zhang, H., & Hoheisel, J. D. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0231-3 · Cited by 96
An overview of kinase downregulators and recent advances in discovery approaches
Wang, B., Wu, H., Hu, C., Wang, H., Liu, J., Wang, W., & Liu, Q. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00826-7 · Cited by 100
Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies
Taylor, J., & Lee, S. C.-W. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22784 · Cited by 108
Merging PROTAC and molecular glue for degrading BTK and GSPT1 proteins concurrently
Yang, Z., Sun, Y., Ni, Z., Yang, C., Tong, Y., Liu, Y., Li, H., & Rao, Y. (2021) · Cell Research · doi:10.1038/s41422-021-00533-6 · Cited by 90
Singh, S. V., Quarni, W., Goralski, M., Wan, S., Jin, H., de Velde, L.-A. V., Fang, J., Wu, Q., Abu‐Zaid, A., Wang, T., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj5405 · Cited by 110
Self-citationChemical strategies to overcome resistance against targeted anticancer therapeutics
Pisa, R., & Kapoor, T. M. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0596-8 · Cited by 86
RNA‐binding motif protein 39 (RBM39): An emerging cancer target
Xu, Y., Nijhuis, A., & Keun, H. C. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15331 · Cited by 90
Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors
LaPlante, G., & Zhang, W. (2021) · Cancers · doi:10.3390/cancers13123079 · Cited by 92
High Throughput Multi-Omics Approaches for Clinical Trial Evaluation and Drug Discovery
Zielinski, J., Luke, J. J., Guglietta, S., & Krieg, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.590742 · Cited by 87
Rui, H., Ashton, K. S., Min, J., Wang, C. W., & Potts, P. R. (2023) · RSC Chemical Biology · doi:10.1039/d2cb00207h · Cited by 94
Remodeling oncogenic transcriptomes by small molecules targeting NONO
Kathman, S. G., Koo, S. J., Lindsey, G. L., Her, H.-L., Blue, S. M., Li, H., Jaensch, S., Remsberg, J. R., Ahn, K., Yeo, G. W.-M., et al. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01270-0 · Cited by 90
Yamanaka, S., Horiuchi, Y., Matsuoka, S., Kido, K., Nishino, K., Maeno, M., Shibata, N., Kosako, H., & Sawasaki, T. (2022) · Nature Communications · doi:10.1038/s41467-021-27818-z · Cited by 86
DNA-encoded library-enabled discovery of proximity-inducing small molecules
Mason, J. W., Chow, Y. T., Hudson, L., Tutter, A., Michaud, G., Westphal, M. V., Shu, W., Ma, X., Tan, Z. Y., Coley, C. W., et al. (2024) · Nature Chemical Biology · doi:10.1038/s41589-023-01458-4 · Cited by 83
The rise and rise of protein degradation: Opportunities and challenges ahead
Hughes, S. J., Testa, A., Thompson, N., & Churcher, I. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.08.006 · Cited by 76
Viswanathan, S. R., Nogueira, M. F., Buss, C. G., Krill-Burger, J. M., Wawer, M. J., Małolepsza, E., Berger, A. C., Choi, P. S., Shih, J., Taylor, A. M., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0155-3 · Cited by 88
PIKES Analysis Reveals Response to Degraders and Key Regulatory Mechanisms of the CRL4 Network
Reichermeier, K. M., Straube, R., Reitsma, J. M., Sweredoski, M. J., Rose, C. M., Moradian, A., den Besten, W., Hinkle, T., Verschueren, E., Petzold, G., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2019.12.013 · Cited by 78
Schreiber, S. L. (2019) · Israel Journal of Chemistry · doi:10.1002/ijch.201800113 · Cited by 77
CRISPR Screen Reveals BRD2/4 Molecular Glue-like Degrader via Recruitment of DCAF16
Shergalis, A. G., Marin, V. L., Rhee, D. Y., Senaweera, S., McCloud, R. L., Ronau, J. A., Hutchins, C. W., McLoughlin, S., Woller, K. R., Warder, S. E., et al. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.2c00747 · Cited by 73
Targeting splicing abnormalities in cancer
Agrawal, A. A., Yu, L., Smith, P. G., & Buonamici, S. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.10.010 · Cited by 79
Aird, D. R., Teng, T., Huang, C. L., Pazolli, E., Banka, D., Cheung-Ong, K., Eifert, C., Furman, C., Wu, Z. J., Seiler, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08150-5 · Cited by 83
Advancing targeted protein degradation for metabolic diseases therapy
Zhou, Q., Xiao, H., Yang, F., Wang, Y., Li, P., & Zheng, Z. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106627 · Cited by 78
Visconte, V., Nakashima, M. O., & Rogers, H. J. (2019) · Cancers · doi:10.3390/cancers11121844 · Cited by 80
Torres, S. E., Gallagher, C. M., Plate, L., Gupta, M., Liem, C. R., Guo, X., Tian, R., Stroud, R. M., Kampmann, M., Weissman, J. S., et al. (2019) · eLife · doi:10.7554/elife.46595 · Cited by 76
“There has been increasing interest in small molecules that induce novel protein-protein interactions with therapeutic potential (de Waal et al., 2016; Han et al., 2017; Krönke et al., 2014; Lu et al., 2014; Krönke et al., 2015; Petzold et al., 2016; Uehara et al., 2017).”
BackgroundUbiHub: a data hub for the explorers of ubiquitination pathways
Liu, L., Damerell, D. R., Koukouflis, L., Tong, Y., Marsden, B. D., & Schapira, M. (2019) · Bioinformatics · doi:10.1093/bioinformatics/bty1067 · Cited by 76
Ubiquitin ligases in cancer: Functions and clinical potentials
Duan, S., & Pagano, M. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.04.008 · Cited by 85
Zhou, J. R., Simon, J. M., Liao, C., Zhang, C., Hu, L., Zurlo, G., Liu, X., Fan, C., Hepperla, A. J., Jia, L., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.06.003 · Cited by 91
Self-citationInducing protein-protein interactions with molecular glues
Che, Y., Gilbert, A. M., Shanmugasundaram, V., & Noe, M. C. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.04.046 · Cited by 70
Han, B. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.014715 · Cited by 71
Liu, S., Hu, Y., Zhang, J., Bao, S., Xian, L., Dong, X., Zheng, W., Li, Y., Gao, H., & Zhou, W. (2019) · Macromolecular Materials and Engineering · doi:10.1002/mame.201800698 · Cited by 70
RNA-binding protein 39: a promising therapeutic target for cancer
Xu, C., Chen, X., Zhang, X., Zhao, D., Dou, Z., Xie, X., Li, H., Yang, H., Li, Q., Zhang, H., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00598-7 · Cited by 78
Induced protein degradation for therapeutics: past, present, and future
Yoon, H., Rutter, J. C., Li, Y.-D., & Ebert, B. L. (2024) · Journal of Clinical Investigation · doi:10.1172/jci175265 · Cited by 67
Monomeric Targeted Protein Degraders
Hanan, E. J., Liang, J., Wang, X., Blake, R. A., Blaquiere, N., & Staben, S. T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00093 · Cited by 69
Villani, F., Pucci, S., Civico, R., Martini, P., Cinti, F. R., & Pantosti, D. (2018) · Tectonics · doi:10.1029/2018tc005175 · Cited by 69
New approaches to target RNA binding proteins
Julio, A. R., & Backus, K. M. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.12.006 · Cited by 76
Expanding the landscape of E3 ligases for targeted protein degradation
Kramer, L. T., & Zhang, X. (2022) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2022.100020 · Cited by 66
Wang, Z., Shaabani, S., Gao, X., Ng, Y. L. D., Sapozhnikova, V., Mertins, P., Krönke, J., & Dömling, A. S. S. (2023) · Nature Communications · doi:10.1038/s41467-023-43614-3 · Cited by 79
The emerging role for Cullin 4 family of E3 ligases in tumorigenesis
Cheng, J., Guo, J., North, B. J., Tao, K., Zhou, P., & Wei, W. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.11.007 · Cited by 74
Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery
Pei, H., Peng, Y., Zhao, Q., & Chen, Y. (2019) · RSC Advances · doi:10.1039/c9ra03423d · Cited by 76
Targeting androgen receptor degradation with PROTACs from bench to bedside
Jia, X., & Han, X. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114112 · Cited by 72
Targeted protein posttranslational modifications by chemically induced proximity for cancer therapy
Peng, Y., Liu, J., Inuzuka, H., & Wei, W. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104572 · Cited by 71
PROTACs: A novel strategy for cancer drug discovery and development
Han, X., & Sun, Y. (2023) · MedComm · doi:10.1002/mco2.290 · Cited by 77
Hypoxia-induced long non-coding RNA DARS-AS1 regulates RBM39 stability to promote myeloma malignancy
Tong, J., Xu, X., Zhang, Z., Ma, C.-N., Xiang, R., Liu, J., Xu, W., Wu, C., Li, J., Zhan, F., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.218289 · Cited by 70
Pan-cancer analysis of clinical relevance of alternative splicing events in 31 human cancers
Zhang, Y., Yan, L., Zeng, J., Zhou, H., Liu, H., Gan, Y., Yao, W., Chen, K., Ye, Z., & Xu, H. (2019) · Oncogene · doi:10.1038/s41388-019-0910-7 · Cited by 75
Therapeutic Modulation of RNA Splicing in Malignant and Non-Malignant Disease
Marabti, E. E., & Abdel-Wahab, O. I. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.04.005 · Cited by 73
Targeted protein degradation in cancers: Orthodox PROTACs and beyond
Li, J., Chen, X., Lü, A., & Liang, C. (2023) · The Innovation · doi:10.1016/j.xinn.2023.100413 · Cited by 95
Ubiquitin-specific proximity labeling for the identification of E3 ligase substrates
Huang, H., Lumpkin, R. J., Tsai, R. W., Su, S., Zhao, X., Xiong, Y., Chen, J., Mageed, N., Donovan, K. A., Fischer, E. S., et al. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01590-9 · Cited by 76
Tan, X., Huang, Z., Pei, H., Jia, Z., & Zheng, J. (2024) · iScience · doi:10.1016/j.isci.2024.110712 · Cited by 66
Comess, K. M., McLoughlin, S. M., Oyer, J. A., Richardson, P. L., Stöckmann, H., Vasudevan, A., & Warder, S. E. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01921 · Cited by 71
Wu, M., Zhao, Y., Zhang, C., & Pu, K. (2024) · ACS Nano · doi:10.1021/acsnano.4c09800 · Cited by 67
Sperling, A. S., Burgess, M., Keshishian, H., Gasser, J. A., Bhatt, S., Jan, M., Słabicki, M., Sellar, R. S., Fink, E. C., Miller, P. G., et al. (2019) · Blood · doi:10.1182/blood.2019000789 · Cited by 64
The COP9 signalosome: A versatile regulatory hub of Cullin-RING ligases
Schulze, E., & Naumann, M. (2022) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2022.08.003 · Cited by 64
Peptidic degron for IMiD-induced degradation of heterologous proteins
Koduri, V., McBrayer, S. K., Liberzon, E., Wang, A. C., Briggs, K. J., Cho, H., & Kaelin, W. G. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818109116 · Cited by 64
Cho, Y. S., Li, S., Wang, X., Zhu, J., Zhuo, S., Han, Y., Yue, T., Yang, Y., & Jiang, J. (2019) · Genes & Development · doi:10.1101/gad.333146.119 · Cited by 69
Slice-PASEF: Maximising Ion Utilisation in LC-MS ProteomicsPreprint
Sinn, L. R., Szyrwiel, Ł., Großmann, J. L., Lau, K., Faisst, K., Qin, D., Mutschler, F., Khoury, L., Leduc, A., Ralser, M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.31.514544 · Cited by 72
Teng, M., & Gray, N. S. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.06.020 · Cited by 66
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
Choucair, K., Imtiaz, H., Uddin, M. H., Nagasaka, M., Al-Hallak, M. N., Philip, P. A., El-Rayes, B., Pasche, B., & Azmi, A. S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02473-8 · Cited by 79
Dai, G., Sun, L., Xu, J., Zhao, G., Tan, Z. H., Wang, C., Sun, X., Xu, K., & Zhong, W. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.006 · Cited by 64
Targeting KRAS4A splicing through the RBM39/DCAF15 pathway inhibits cancer stem cells
Chen, W.-C., To, M. D., Westcott, P. M. K., Delrosario, R., Kim, I.-J., Philips, M. R., Tran, Q., Bollam, S., Goodarzi, H., Bayani, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24498-7 · Cited by 64
Bewersdorf, J. P., Stahl, M., Taylor, J., Mi, X., Chandhok, N. S., Watts, J., Derkach, A., Wysocki, M., Lu, S. X., Bourcier, J., et al. (2023) · Leukemia · doi:10.1038/s41375-023-02050-4 · Cited by 62
“1B) [13, 14].”
Wu, H., Yao, H., He, C., Jia, Y., Zhu, Z., Xu, S., Li, D., & Xu, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.03.019 · Cited by 65
E3 ligase ligand optimization of Clinical PROTACs
Jiang, H., Xiong, H., Gu, S.-X., & Wang, M. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1098331 · Cited by 68
Molecular glue concept solidifies
Baek, K., & Schulman, B. A. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0414-3 · Cited by 65
Ito, T., Yamaguchi, Y., & Handa, H. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.012 · Cited by 58
Novel approaches to targeted protein degradation technologies in drug discovery
Xue, Y., Bolinger, A. A., & Zhou, J. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2187777 · Cited by 62
Screening for molecular glues – Challenges and opportunities
Holdgate, G. A., Bardelle, C., Berry, S. K., Lanne, A., & Cuomo, M. E. (2023) · SLAS DISCOVERY · doi:10.1016/j.slasd.2023.12.008 · Cited by 67
Geiger, T. M., Schäfer, S. C., Dreizler, J. K., Walz, M., & Hausch, F. (2022) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2021.100018 · Cited by 52
Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design
Mi, D., Li, Y., Gu, H., Li, Y., & Chen, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115444 · Cited by 59
Profiling the Landscape of Drug Resistance Mutations in Neosubstrates to Molecular Glue Degraders
Gosavi, P. M., Ngan, K. C., Yeo, M. J. R., Su, C., Li, J., Lue, N. Z., Hoenig, S. M., & Liau, B. B. (2022) · ACS Central Science · doi:10.1021/acscentsci.1c01603 · Cited by 56
Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation
Dou, Z., Zhao, D., Chen, X., Xu, C., Jin, X., Zhang, X., Wang, Y., Xie, X., Li, Q., Di, C., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02001-w · Cited by 61
Prospecting for molecular glues
den Besten, W., & Lipford, J. R. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0620-z · Cited by 55
Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs
Naito, M., Ohoka, N., Shibata, N., & Tsukumo, Y. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00849 · Cited by 60
Investigating the Potential Roles of SINEs in the Human Genome
Zhang, X.-O., Pratt, H., & Weng, Z. (2021) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-111620-100736 · Cited by 58
Luo, X., Archibeque, I., Dellamaggiore, K., Smither, K., Homann, O. R., Lipford, J. R., & Mohl, D. A. (2022) · iScience · doi:10.1016/j.isci.2022.103985 · Cited by 60
Molecular glues and induced proximity: An evolution of tools and discovery
Robinson, S. A., Co, J., & Banik, S. M. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.04.001 · Cited by 63
Targeting RNA splicing modulation: new perspectives for anticancer strategy?
Lv, X., Sun, X., Gao, Y., Song, X., Hu, X., Gong, L., Li, H., He, M., & Wei, M. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03279-w · Cited by 61
Unraveling Host-Gut Microbiota Dialogue and Its Impact on Cholesterol Levels
Villette, R., Pukar, K. C., Béliard, S., Salas-Tapia, M. F., Rainteau, D. P., Guérin, M., & Lesnik, P. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00278 · Cited by 58
Alternative Splicing: Expanding the Landscape of Cancer Biomarkers and Therapeutics
Bessa, C., Matos, P., Jordan, P., & Gonçalves, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239032 · Cited by 56
Burslem, G. M., Ottis, P., Jaime‐Figueroa, S., Morgan, A., Cromm, P. M., Toure, M., & Crews, C. M. (2018) · ChemMedChem · doi:10.1002/cmdc.201800271 · Cited by 52
A critical evaluation of the approaches to targeted protein degradation for drug discovery
Chopra, R., Sadok, A., & Collins, I. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2019.02.002 · Cited by 53
Clinical Translation of Targeted Protein Degraders
Kong, N. R., & Jones, L. H. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2985 · Cited by 59
Induced proximity-based therapeutic modalities
King, E. A., Meyers, M., & Nomura, D. K. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01316-z · Cited by 73
Targeting the spliceosome machinery: A new therapeutic axis in cancer?
Eymin, B. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114039 · Cited by 55
A mass spectrometry-based proteome map of drug action in lung cancer cell lines
Ruprecht, B., Bernardo, J. D., Wang, Z., Mo, X., Ursu, O., Christopher, M., Fernandez, R. B., Zheng, L., Dill, B. D., Wang, H., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0572-3 · Cited by 61
Decoding the messaging of the ubiquitin system using chemical and protein probes
Henneberg, L. T., & Schulman, B. A. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.03.009 · Cited by 56
MYC regulates a pan-cancer network of co-expressed oncogenic splicing factors
Urbanski, L. M., Brugiolo, M., Park, S., Angarola, B. L., Leclair, N. K., Yurieva, M., Palmer, P., Sahu, S. K., & Anczuków, O. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111704 · Cited by 61
Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic
Bewersdorf, J. P., & Abdel-Wahab, O. I. (2022) · Genes & Development · doi:10.1101/gad.349368.122 · Cited by 55
Splicing modulators: on the way from nature to clinic
Schneider‐Poetsch, T., Chhipi-Shrestha, J. K., & Yoshida, M. (2021) · The Journal of Antibiotics · doi:10.1038/s41429-021-00450-1 · Cited by 56
Liu, C., Shen, M., Liu, Y., Manhas, A., Zhao, S. R., Zhang, M., Belbachir, N., Ren, L., Zhang, J. Z., Caudal, A., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.10.007 · Cited by 57
Ubiquitin-Dependent Regulation of Stem Cell Biology
Werner, A. A., Manford, A. G., & Rapé, M. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.04.002 · Cited by 56
Proteomic characterization of post-translational modifications in drug discovery
Zhai, L., Chen, K., Hao, B., & Tan, M. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-01017-y · Cited by 59
Xu, Y., Spear, S., Ma, Y., Lorentzen, M. P., Gruet, M., McKinney, F., Xu, Y., Wickremesinghe, C., Shepherd, M., McNeish, I. A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113307 · Cited by 68
Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence
Duran-Frigola, M., Cigler, M., & Winter, G. E. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c11098 · Cited by 50
Metadata
- Authors
- Han, T., Goralski, M., Gaskill, N., Capota, E., Kim, J., Ting, T. C., Xie, Y., Williams, N. S., & Nijhawan, D.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Corresponding author
- Goralski, Maria
- Gaskill, Nicholas
- Nijhawan, Deepak
- ORCID
- Venue
- Science
- Published
- 2017-04-28
- Volume
- 356
- Issue
- 6336
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2596064219
- Cited by
- 762
- References
- 55
- Citations by year
- 2026: 72 · 2025: 86 · 2024: 122 · 2023: 99 · 2022: 86 · 2021: 99 · 2020: 86 · 2019: 56 · 2018: 40 · 2017: 15
- FWCI
- 22.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Welch Foundation (I-1879)
- Damon Runyon Cancer Research Foundation (CI-68-13)
- Cancer Prevention and Research Institute of Texas (RP150596)
- Life Sciences Research Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- indisulam, sulfonamides, RBM39, DCAF15, pre-mRNA splicing, splicing inhibition, proteasomal degradation, polyubiquitination, anticancer agents, drug resistance, biomarkers
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Mutation, Neoplasms, Nuclear Proteins, RNA Splicing, Sulfonamides, RNA-Binding Proteins, Mice, Knockout, Drug Resistance, Neoplasm, Amino Acid Substitution, Xenograft Model Antitumor Assays, Ubiquitin-Protein Ligase Complexes, Cell Line, Tumor, Proteasome Endopeptidase Complex, Mice, Biomarkers, Pharmacological, Ubiquitination, Molecular Targeted Therapy, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.